Retatrutide and MK-677 (Ibutamoren)
No clinical trial has studied this combination. MK-677 is not approved for human use. Retatrutide is not FDA approved. MK-677's appetite-stimulating mechanism may directly oppose retatrutide's appetite suppression. All rationale is anecdotal.
This page reviews what is known about combining retatrutide with MK-677 (ibutamoren): the regulatory status of each compound, what human evidence exists, theoretical rationale discussed in online communities, and the notable pharmacodynamic conflict between the two compounds.
What Each Compound Is
Why People Search for This Combination
SARM and peptide communities discuss MK-677 with retatrutide for body recomposition. MK-677 is popular because it is oral and has documented GH-stimulating effects. The combination is discussed as a way to stimulate GH release for lean mass support while using retatrutide for fat loss. A notable pharmacodynamic conflict exists: MK-677 acts as a ghrelin receptor agonist, which stimulates appetite — the opposite of retatrutide's appetite-suppressing mechanism.
Human Evidence
No published clinical trial has studied retatrutide combined with MK-677. MK-677 has Phase 2 human data for GH deficiency and muscle wasting but no approved indication. Retatrutide's Phase 2 trial showed up to 24.2% mean weight loss at 48 weeks. No body composition data exists for the combination. The opposing effects on appetite represent a documented pharmacodynamic conflict.
Theoretical Rationale
The theoretical rationale is that MK-677's GH secretagogue effects could support lean mass during retatrutide-induced fat loss. However, MK-677 acts as a ghrelin receptor agonist — ghrelin is the primary hunger hormone. This mechanism directly opposes retatrutide's appetite suppression through GLP-1 and other pathways. Whether retatrutide's appetite suppression would overcome MK-677's appetite stimulation, or whether the net effect would be attenuated weight loss, is unknown.
Known and Plausible Risks
- Retatrutide: GI adverse events, heart rate increase, gallbladder effects, class-level precautions for thyroid C-cell tumors and pancreatitis
- MK-677: Increased appetite (ghrelin agonism), water retention, insulin resistance, potential effects on blood glucose; long-term safety unknown
- Combined: MK-677's appetite-stimulating effects may directly oppose retatrutide's appetite suppression; unknown interaction risks
Body Composition Considerations
Retatrutide's Phase 2 data showed significant fat mass reduction with some lean mass loss. MK-677 has documented effects on GH and IGF-1 levels and some evidence for lean mass support in clinical populations. The opposing appetite effects represent a meaningful pharmacodynamic conflict that could attenuate retatrutide's weight loss efficacy. No body composition data exists for the combination.
What People Are Discussing Online
Reddit communities (r/sarmssourcetalk, r/Peptides) discuss MK-677 with retatrutide. Some users report that MK-677's appetite stimulation partially counteracts retatrutide's appetite suppression, reducing weight loss. Others report using lower MK-677 doses to minimize this conflict. These reports are anecdotal and not systematically collected.
Regulatory and Legal Context
MK-677 is not approved for human use. It is sold as a research chemical. Retatrutide is not FDA approved. Using two unapproved or investigational compounds simultaneously outside a supervised clinical context carries significant legal and medical risks.
Frequently Asked Questions
No. No published clinical trial has studied this combination. MK-677 is not approved for human use. No safety or efficacy data exists for the combination.
MK-677 acts as a ghrelin receptor agonist, which stimulates appetite. Retatrutide suppresses appetite through GLP-1 and other mechanisms. These opposing effects on appetite represent a notable theoretical pharmacodynamic conflict.
MK-677 is not approved for human use. It is sold as a research chemical. Use of unapproved compounds carries unknown safety risks.
Ready to Start Your Physician Review?
$477 one-time payment. No membership. No recurring billing. No charge unless approved.
START PHYSICIAN REVIEW